---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-22-029358"
form_type: "8-K"
ticker: "BLGO"
cik: "0000880242"
company_name: "BIOLARGO, INC."
filed_at: "2022-12-19T23:59:59+00:00"
generated_at: "2026-06-21T02:59:05.670359+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# BioLargo secures $10M equity line from Lincoln Park Capital; issues 1.25M commitment shares

## Summary
- BioLargo entered purchase agreement with Lincoln Park Capital for up to $10M of common stock over 36 months.
- Company may sell shares at its discretion; Lincoln Park obligated to purchase subject to conditions.
- As consideration, BioLargo issued 1.25M commitment shares and will pay $250k cash fee after $3M in sales.
- Proceeds will be used for working capital and general corporate purposes.
- Stock sales capped at 4.99% beneficial ownership; no short sales allowed by Lincoln Park.

## SEC filing metadata
- accession: 0001437749-22-029358
- form_type: 8-K
- ticker: BLGO
- cik: 0000880242
- company_name: BIOLARGO, INC.
- filed_at: 2022-12-19T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/880242/000143774922029358/0001437749-22-029358-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/880242/000143774922029358/blgo20221213_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-22-029358
- JSON: https://secwatch.observer/filing/0001437749-22-029358.json
- Plain text: https://secwatch.observer/filing/0001437749-22-029358.txt

## Key facts
- Material Agreements
  BIOLARGO, INC. entered into Registration Rights Agreement with Lincoln Park Capital Fund, LLC (effective 2022-12-12).
  - Action: entry
  - Counterparty: Lincoln Park Capital Fund, LLC
  - Effective: 2022-12-12
  source text: On December 13, 2022, BioLargo, Inc. (the “Company” or “we”) entered into a purchase agreement, dated as of December 13, 2022 (the “Purchase Agreement”), and a registration rights agreement, dated as of December 12, 2022 (the “Registration Rights Agreement”), with Lincoln Park Capital Fund, LLC (“Lincoln Park”)
  evidence_url: https://www.sec.gov/Archives/edgar/data/880242/000143774922029358/0001437749-22-029358-index.htm
- Material Agreements
  BIOLARGO, INC. entered into Purchase Agreement with Lincoln Park Capital Fund, LLC valued at up to $10.0 million (effective 2022-12-13).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: Lincoln Park Capital Fund, LLC
  - Value: up to $10.0 million
  - Effective: 2022-12-13
  source text: On December 13, 2022, BioLargo, Inc. (the “Company” or “we”) entered into a purchase agreement, dated as of December 13, 2022 (the “Purchase Agreement”), and a registration rights agreement, dated as of December 12, 2022 (the “Registration Rights Agreement”), with Lincoln Park Capital Fund, LLC (“Lincoln Park”), pursuant to which Lincoln Park has committed to purchase up to $10.0 million of the Company’s common stock
  evidence_url: https://www.sec.gov/Archives/edgar/data/880242/000143774922029358/0001437749-22-029358-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.